miR-499a inhibits the proliferation and apoptosis of prostate cancer via targeting UBE2V2

[1]  M. Yi,et al.  The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer , 2021, World Journal of Surgical Oncology.

[2]  Cheng-Ruei Liu,et al.  CircLRP6 contributes to prostate cancer growth and metastasis by binding to miR-330-5p to up-regulate NRBP1 , 2021, World Journal of Surgical Oncology.

[3]  Lei Ma,et al.  Potential role of chimeric genes in pathway-related gene co-expression modules , 2021, World Journal of Surgical Oncology.

[4]  Yuting He,et al.  Pan-Cancer Analysis of m5C Regulator Genes Reveals Consistent Epigenetic Landscape Changes in Multiple Cancers , 2020, SSRN Electronic Journal.

[5]  Ping Li,et al.  UBE2V2 Positively Correlates With PD-L1 Expression and Confers Poor Patient Survival in Lung Adenocarcinoma , 2021, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  L. Elmore,et al.  Blueprint for cancer research: Critical gaps and opportunities , 2020, CA: a cancer journal for clinicians.

[7]  A. Dharmarajan,et al.  Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p. , 2020, Life sciences.

[8]  H. Weir,et al.  Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.

[9]  David P. Smith,et al.  Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study , 2020, BMJ.

[10]  Xianjin Zhu,et al.  Utility of red cell distribution width as a diagnostic and prognostic marker in non-small cell lung cancer , 2020, Scientific Reports.

[11]  M. Gleave,et al.  LIN28B promotes the development of neuroendocrine prostate cancer. , 2020, The Journal of clinical investigation.

[12]  B. Plosky,et al.  The Cycle of Basic and Applied Cancer Research. , 2020, Molecules and Cells.

[13]  Di Wang,et al.  Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16 , 2020, World Journal of Surgical Oncology.

[14]  Zheyan Liu,et al.  MiR-499a-5p Inhibits Proliferation, Invasion, Migration, and Epithelial–Mesenchymal Transition, and Enhances Radiosensitivity of Cervical Cancer Cells via Targeting eIF4E , 2020, OncoTargets and therapy.

[15]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[16]  I. Mills,et al.  miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. , 2019, Cancer letters.

[17]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.

[18]  W. Xia,et al.  Exosomal miR‐499a‐5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma , 2019, Experimental cell research.

[19]  Xiao-hong Ma,et al.  Increased expression of a novel miRNA in peripheral blood is negatively correlated with hippocampal volume in patients with major depressive disorder. , 2019, Journal of affective disorders.

[20]  L. Holmberg,et al.  Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29‐Year Follow‐up , 2018, The New England journal of medicine.

[21]  Jennifer Y. Zhang,et al.  UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. , 2018, Cancer research.

[22]  S. Zhang,et al.  Ube2V2 Is a Rosetta Stone Bridging Redox and Ubiquitin Codes, Coordinating DNA Damage Responses , 2018, ACS central science.

[23]  S. Zimmerman,et al.  Engineering the Surface of Therapeutic "Living" Cells. , 2018, Chemical reviews.

[24]  P. Stattin,et al.  Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. , 2017, European urology.

[25]  M. Hummel,et al.  miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer , 2017, Cell Death and Disease.

[26]  Ri-tai Huang,et al.  TBX20 loss-of-function mutation responsible for familial tetralogy of Fallot or sporadic persistent truncus arteriosus , 2017, International journal of medical sciences.

[27]  K. D. Sørensen,et al.  The Potential of MicroRNAs as Prostate Cancer Biomarkers. , 2016, European urology.

[28]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Nykter,et al.  MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. , 2015, European urology.

[30]  J. Li,et al.  Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies , 2014, World Journal of Surgical Oncology.

[31]  M. Loda,et al.  MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. , 2012, Cancer discovery.

[32]  L. Santarpia,et al.  Breast cancer assessment tools and optimizing adjuvant therapy , 2010, Nature Reviews Clinical Oncology.

[33]  J. Sale,et al.  UBE2V2 (MMS2) is not required for effective immunoglobulin gene conversion or DNA damage tolerance in DT40. , 2005, DNA repair.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  M. Rehli,et al.  Molecular cloning of a 1alpha,25-dihydroxyvitamin D3-inducible transcript (DDVit 1) in human blood monocytes. , 1997, Biochemical and biophysical research communications.